Vimta Labs

Vimta Labs delivered its highest ever quarterly sales revenue in Q2 FY26, reaching INR1,045 million, a significant 22.3% year-on-year increase. This robust top-line growth translated into strong profitability, with EBITDA at INR369 million, up 20.6% YoY, and an EBITDA margin of 35.3%. Net profit for the quarter stood at INR199 million, growing 17.1% YoY, with a PAT margin of 19.1%.

Pharmaceutical research and testing, along with food testing services, were the primary contributors to the strong revenue growth in Q2 FY26. These two segments collectively account for approximately 85% of the company's total revenue, with pharma contributing around 65% and food testing around 20%. The electrical and electronics testing and environmental testing services maintained steady performance. Management noted that margins are generally similar across all verticals, with environmental testing being a slight exception.

The company has expanded its infrastructure and capacities across pharmaceuticals, food, and electrical & electronic testing, with new facilities already commercialized. The biologics contract research and development services project is progressing as per schedule, with commercialization anticipated by Q1 FY27. The facility will be ready by the end of Q3 FY26, followed by qualifications. The strategy for biologics involves integrating services from preclinical to clinical research, analytical components, and backward integration into formulation development.

Vimta Labs maintains a net debt-free balance sheet, with cash and cash equivalents, including bank balances, totaling INR545 million. The company is on track to meet its FY26 capex target of INR100 crores. Specifically for biologics, an outlay of approximately INR25 crores is planned for FY26, with a similar amount projected for FY27, demonstrating a focused investment strategy in high-growth areas.

Management indicated that the overall market growth rates for their sectors (pharma, food, electronics) are around 7.5% to 9%, suggesting Vimta Labs is gaining market share with its 20-25% growth. The company faces competition from both domestic players and international CROs like SGS, Eurofins, and Charles River. The increasing trend of innovator companies outsourcing for IP protection and the growth of complex product development are seen as positive drivers for demand in analytical and research services.

The regulatory environment, including the BIOSECURE Act and the Food Safety and Standards Act, is viewed favorably, as stricter regulations tend to increase demand for testing services. Management highlighted that there have been no significant changes in regulations impacting their business. The company continuously invests in new technologies and equipment to enhance testing processes, reduce manpower dependency, and improve productivity, positioning itself as an early adopter of technological advancements.